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Abstract 
Background: Therapeutic efficacy studies in uncomplicated Plasmodium falciparum malaria are confounded by new 
infections, which constitute competing risk events since they can potentially preclude/pre-empt the detection of 
subsequent recrudescence of persistent, sub-microscopic primary infections.
Methods: Antimalarial studies typically report the risk of recrudescence derived using the Kaplan–Meier (K–M) 
method, which considers new infections acquired during the follow-up period as censored. Cumulative Incidence 
Function (CIF) provides an alternative approach for handling new infections, which accounts for them as a competing 
risk event. The complement of the estimate derived using the K–M method (1 minus K–M), and the CIF were used to 
derive the risk of recrudescence at the end of the follow-up period using data from studies collated in the WorldWide 
Antimalarial Resistance Network data repository. Absolute differences in the failure estimates derived using these two 
methods were quantified. In comparative studies, the equality of two K–M curves was assessed using the log-rank 
test, and the equality of CIFs using Gray’s k-sample test (both at 5% level of significance). Two different regression 
modelling strategies for recrudescence were considered: cause-specific Cox model and Fine and Gray’s sub-distribu-
tional hazard model.
Results: Data were available from 92 studies (233 treatment arms, 31,379 patients) conducted between 1996 and 
2014. At the end of follow-up, the median absolute overestimation in the estimated risk of cumulative recrudescence 
by using 1 minus K–M approach was 0.04% (interquartile range (IQR): 0.00–0.27%, Range: 0.00–3.60%). The overesti-
mation was correlated positively with the proportion of patients with recrudescence [Pearson’s correlation coefficient 
(ρ): 0.38, 95% Confidence Interval (CI) 0.30–0.46] or new infection [ρ: 0.43; 95% CI 0.35–0.54]. In three study arms, the 
point estimates of failure were greater than 10% (the WHO threshold for withdrawing antimalarials) when the K–M 
method was used, but remained below 10% when using the CIF approach, but the 95% confidence interval included 
this threshold.
Conclusions: The 1 minus K–M method resulted in a marginal overestimation of recrudescence that became increas-
ingly pronounced as antimalarial efficacy declined, particularly when the observed proportion of new infection 
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Background
A competing risk is an event which precludes the occur-
rence of the primary event of interest [1]. The primary 
endpoint in therapeutic efficacy studies in uncompli-
cated Plasmodium falciparum malaria is recurrence of 
the parasite during the study follow-up which caused the 
original infection (recrudescence). Malaria recurrence 
may also be caused by a heterologous parasite, which can 
be either a newly acquired infection with P. falciparum, 
or another species of Plasmodium. In certain scenar-
ios, such as when the parasite load of a newly acquired 
infection outnumbers the low level of parasitaemia of an 
existing infection, the recrudescent parasites may not be 
detected (Fig. 1a). In such a scenario, a new infection can 
pre-empt the patency of a recrudescent infection thereby 
constituting a competing risk event (Table 1). 
The Kaplan–Meier (K–M) survival analysis is cur-
rently the approach recommended by the World Health 
Organization (WHO) for deriving antimalarial efficacy, 
where a competing risk event of a new infection is con-
sidered as a censored observation on the day of occur-
rence [2]. The complement of K–M estimate (1 minus 
K–M) is frequently reported in standalone efficacy 
studies as the WHO recommends replacing an exist-
ing treatment with an alternative regimen if the derived 
estimate of cumulative failure exceeds 10%. Several 
studies in clinical and statistical literature has shown 
that the 1 minus K–M approach provides an upwards 
was high. The CIF approach provides an alternative approach for derivation of failure estimates in antimalarial trials, 
particularly in high transmission settings.
Keywords: Plasmodium falciparum, Treatment efficacy study, Competing risk event
Fig. 1 Situational competitiveness of newly emergent infections. Adapted from White-2002 [44]. The blue line represents a hypothetical drug 
concentration of partner component, the green and red lines represent scenarios for parasite burden versus time profiles following treatment for 
an infection where all the parasites are completely killed resulting in cure (green) and an infection where parasites are initially killed by high drug 
levels but with drug levels below the minimum inhibitory concentration (MIC), net parasite growth results in subsequent recrudescence (red). 
The orange line represents parasite-time profiles for a new infection. The left y-axis is for parasite density, and the right y-axis shows drug levels at 
hypothetical units. The vertical dotted line is the administrative end of the study follow-up. The horizontal dotted line represents the microscopic 
limit of detection for parasites. a Parasite population from a new inoculation out-competes the parasite population which caused the disease thus 
precluding recrudescence. In this situation, new infection is a biologically competing risk event. b In this situation new infection can be thought 
of as biologically competing risk event which doesn’t prevent recrudescence being observed. c The parasite population which caused the disease 
is completely eliminated. Here, new infection is not a competing event. d In this situation, the parasite population which caused the disease and 
which is derived from a novel inoculation appear at the same time
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biased estimate of the cumulative risk for the event of 
interest in the presence of competing risk events [1, 3–
6]. In a re-analysis of an antimalarial efficacy trial from 
Uganda, it was demonstrated that the derived estimate 
of cumulative recrudescence using the 1 minus K–M 
approach can lead to a counter-intuitive scenario where 
the sum of the individual risk of recurrence for recru-
descence and new infection is greater than for the com-
posite endpoint of overall recurrence (see Figure  4 in 
[7]). An alternative approach for deriving failure esti-
mate is to use the Cumulative Incidence Function (CIF) 
[8] (see Additional file 1: Section 1).
The presence of competing risk events can have fur-
ther implications for comparative drug trials and regres-
sion modelling. First, comparative antimalarial trials 
utilize the widely used log-rank test to compare the effi-
cacy between two drugs. An alternative approach, which 
compares the difference in cumulative risk between two 
groups by accounting for competing risk events, is the 
Gray’s k-sample test [9] (see Additional file 1: Section 2). 
Simulation studies have reported different performances 
of these two approaches depending on the underlying 
effect of the drug on the primary event of interest and on 
competing risk events [5, 10]. Second, in the presence of 
competing risk events, regression modelling can be car-
ried out either using the Cox’s proportional hazard model 
or using the Fine and Gray’s model [11]. The former is 
based on modelling of the cause-specific hazard func-
tion whereas the latter is based on the modelling of sub-
distribution hazard function. The differences between the 
cause-specific and sub-distribution hazard functions, and 
the underlying regression models are explained in Addi-
tional file 1: Sections 2, 3 and 4.
The application of competing risk survival analysis 
approach has gathered little attention in the antimalar-
ial literature [7, 12]. This research aimed to address this 
research gap and there were three specific objectives:
 i. To investigate the influence of competing risk 
events on the derived estimate of polymerase 
chain reaction (PCR) confirmed recrudescence in a 
stand-alone trial;
 ii. To investigate the influence of competing risk 
events on the estimation of comparative efficacy 
between antimalarial drugs;
 iii. To demonstrate regression modelling approaches 
in the presence of competing risk events.
Methods
Identification of studies for potential inclusion
The WorldWide Antimalarial Resistance Network 
(WWARN) repository contains a large collection of stand-
ardized data on antimalarial drugs [13]. Studies in the 
WWARN data repository were eligible for inclusion in the 
current analysis, if the data were from prospective clinical 
efficacy studies of uncomplicated P. falciparum (alone or 
mixed infections with Plasmodium vivax) in which patients 
were treated with one of the following fixed-dose regimens: 
artemether–lumefantrine (AL), dihydroartemisinin–pipe-
raquine (DP), artesunate–amodiaquine (ASAQ), or artesu-
nate–mefloquine (ASMQ). All studies also had to have 
applied molecular PCR genotyping to distinguish recru-
descence from new infection. Studies on prophylactic use 
of antimalarials, severe malaria, pregnant women, patients 
with hyperparasitaemia, healthy volunteers, and travellers 
were excluded. Treatment outcomes were generated based 
on the definitions outlined in the WWARN Data Manage-
ment and Statistical Analysis Plan [14].
Statistical analyses
Derivation of cumulative failure estimates in standalone 
studies
The estimate of cumulative recrudescence at the end of 
study follow-up was derived using two methods: (i) the 
Table 1 Possible outcomes in antimalarial studies of uncomplicated P. falciparum malaria
Possible outcomes Description
Recrudescence of P. falciparum Recurrent infection caused by the parasites that survived treatment. This is the primary end-
point in antimalarial efficacy studies of uncomplicated P. falciparum malaria
Novel infections due to P. falciparum or P. vivax Recurrent infection due to a new parasite strain or strains during the follow-up. This can be due 
to a different Plasmodium species or due to the same species but different genotype from the 
initial parasite infection
Indeterminate recurrent infection Recurrent infection with the same parasite species but in which molecular analysis is unable to 
discriminate between a recrudescent or new infection (e.g. due to unsuccessful amplification 
of DNA). These patients are usually excluded when deriving efficacy estimates
Patients in whom follow-up is curtailed before the 
end of the study or the occurrence of the primary 
event
Incomplete follow-up can occur in patients who fail to return to the clinic for follow-up, with-
draw their consent or other reasons for discontinuation. These patients are censored in K–M 
survival analysis and excluded from per protocol analysis
Adequate clinical and parasitological response (ACPR) Treatment success, defined as the absence of parasitaemia at the end of the study follow-up
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Kaplan–Meier method and (ii) the Cumulative Inci-
dence Function (CIF) estimator (p. 255 of [15]). New 
infections and indeterminate outcomes were consid-
ered as censored at the time of their occurrence in the 
K–M approach whereas they were considered as differ-
ent categories of competing events in the CIF approach. 
The difference in derived estimates of PCR confirmed 
recrudescence using these two different approaches was 
calculated and expressed in absolute scale. The effect of 
length of study follow-up, observed proportion of events 
and competing events per arm on the magnitude of the 
difference in the derived estimates between the two 
approaches was explored.
Impact of competing risk events in comparative efficacy 
studies
For comparative efficacy studies where the interest lies 
in establishing the difference between two drugs in 
terms of primary endpoint of interest (recrudescence), 
two different approaches were used: (i) the log-rank 
test to compare the equality of the K–M curves, and (ii) 
Gray’s k-sample test to compare the equality of the CIFs 
[16]. In the absence of competing risk events, the result 
of Gray’s  k-sample test will be identical to that derived 
by the log-rank test [17]. In the log-rank test, new infec-
tions and indeterminate recurrence were considered as 
censored.
Regression models for recrudescence and new infection
In the presence of competing risk events, regression 
modelling can be carried out either on the cause-specific 
hazard function (using Cox proportional hazards model) 
or the sub-distribution hazard function (using Fine and 
Gray model) (see Additional file  1: Sections  3 and 4). 
A subset of data from a large multi-centre study (The 
4ABC Trial [18]), which enrolled children aged less than 
5 years in Africa was used to illustrate the two regression 
approaches in the presence of competing risk events.
The regression parameters of the Fine and Gray 
model were expressed as a sub-distribution hazard ratio 
(sdHR), and the output of the cause-specific Cox model 
as a cause-specific hazard ratio (csHR). Regression mod-
els were fitted without variable selection as the aim was 
to use the fitted model for risk prediction (rather than 
identification of putative factors) using the known con-
founders: age, baseline parasitaemia, and treatment regi-
men. The same set of covariates was used in models for 
recrudescence and new infection as recommended by 
Marubini and Valsechhi (p. 347) [19]. The fitted regres-
sion models were then used to estimate the predicted risk 
of recrudescence on day 28 (Additional file 1: Section 5).
Software
All the analyses were carried out using R software 
(Version 3.2.4) [20]. The log-rank test was carried out 
using the survdiff function in the survival package and 
Gray’s  k-sample test was performed using the cuminc 
function in the cmprsk package.
Results
Characteristics of the studies and patients included
Individual patient data were available from 92 studies 
(31,507 patients) carried out in 169 trial sites with a total 
of 233 treatment arms (see Additional file 2 for details of 
the studies included). A total 186 arms (79.8%) were from 
Africa, 45 (19.3%) from Asia and 2 (0.85%) were from 
South America. The duration of follow-up was 28 days in 
120 (51.5%) treatment arms, 42 days in 76 (32.6%) arms, 
and 63 days in 37 (15.9%) arms. Overall, 16,313 (51.9%) 
patients were treated with AL, 9064 (28.9%) with DP, 
4782 (15.2%) with ASAQ and 1220 (3.9%) with ASMQ. 
Baseline characteristics of the patients are presented in 
Table 2.
Study outcomes
In Africa, a total of 4534 (18.8%) recurrent infections 
were documented, of which 553 (2.3%) were recrudes-
cent infections; the proportion of recrudescent failures 
was 2.5% (356/14,027) for AL, 2.3% (112/4862) for DP, 
1.6% (70/4482) for ASAQ and 1.9% (15/810) for ASMQ 
(Additional file 3: Section 1). In Asia, 8.5% (579/6787) of 
patients had recurrent infection, of which 126 (21.8%) 
were recrudescences. The proportion of patients with 
recrudescences in Asia was 2.7% (58/2127) for AL, 5.3% 
(16/300) for ASAQ, 3.2% (13/410) for ASMQ and 1.0% 
for DP (39/3950). In South America, there were 3 recru-
descences (0.7%) and 4 new infections (1.0%). Of the 233 
treatment arms, 83 (35.6%) arms reported no recrudes-
cent infections, and 199 (85.4%) arms had at least one 
new infection observed. The observed proportion for the 
different event types are presented in Fig. 2.
Standalone efficacy studies
Risk of Plasmodium falciparum recrudescence
In 91 arms (39%), there was either absence of recurrence 
or only recrudescence or new infections were observed. 
In these arms, the failure estimates derived from both 
methods were identical. In the remaining 142 arms (61%), 
the 1 minus K–M method was associated with a marginal 
overestimation of the risk of PCR confirmed recrudes-
cence compared to the CIF by a median of 0.04% [IQR: 
0.00–0.27%; Range: 0.00–3.60%] (Fig.  3, upper panel). 
The degree of overestimation was progressively larger 
with increasing study follow-up duration; the median 
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overestimation being 0.006% [IQR: 0.00–0.07%; Range: 
0.00–2.54%] on day 28, 0.15% [IQR: 0.00–0.57%; Range: 
0.00–3.23%] on day 42, and 0.56% [IQR: 0.11–1.12%; 
Range: 0.00–3.60%] on day 63 (Table 3). The magnitude 
of overestimation also correlated with the observed 
proportion of new infections [Pearson’s correlation coef-
ficient: 0.43; 95% CI 0.35–0.54] and the observed propor-
tion of recrudescences [Pearson’s correlation coefficient: 
0.38, 95% CI 0.30–0.46] (Fig. 3, Table 3). 
The maximum overestimation was 3.6%, which 
occurred in an artesunate–mefloquine arm in Balonghin 
site in Burkina Faso (n = 66), an area of high transmis-
sion [21]. In this arm, the day 63 failure estimate derived 
using the K–M method was 20.0% [95% CI 0.0–55.1] 
and the corresponding CIF estimate was 16.4% [95% CI 
0.0–48.6]. In 9.0% (21/233) of the treatment arms, the 
overestimation was greater than 1%, in 4.3% (10/233) this 
was greater than 2%, and in 2.6% (6/233) the difference 
was greater than 3%. All of the 21 study sites where the 
overestimation exceeded 1% were from Africa except one 
from Papua New Guinea, where 51% of patients with par-
asite recurrence were due to to P. vivax.
Study sites where estimate of PCR‑confirmed recrudescence 
exceeded 10% using complement of K–M
In three (1.3%) study arms, the estimated cumulative 
risk of recrudescence exceeded 10% (the WHO thresh-
old for withdrawing first line therapy) based on the 
K–M method, but the CIF estimates were all less than 
10% (Table 4). Similarly, in 9 (3.9%) study arms, the esti-
mated failures were greater than 5% (the WHO threshold 
Table 2 Baseline characteristics of patients included
AL artemether–lumefantrine, ASAQ artesunate–amodiaquine, ASMQ artesunate–mefloquine, DP dihydroartemisinin–piperaquine, IQR interquartile range, SD standard 
deviation, N number of patients
a Column percentages presented in parenthesis
Baseline characteristics AL (1996–2014) ASAQ (2002–2014) ASMQ (2002–2013) DP (2002–2013) Total (1996–2014)
N 16,373 4850 1220 9064 31,507
Gender
 Femalea 7394 (45.2%) 2253 (46.5%) 591 (48.4%) 3464 (38.2%) 13,702 (43.5%)
Age (years)a
 Mean age ± SD (years) 8.3 ± 10.66 7.0 ± 9.21 11.9 ± 13.37 13.5 ± 14.09 9.8 ± 11.94
 < 1 year 924 (5.6%) 312 (6.4%) 65 (5.3%) 386 (4.3%) 1687 (5.4%)
 1 to < 5 years 8629 (52.7%) 2895 (59.7%) 522 (42.8%) 3736 (41.2%) 15,782 (50.1%)
 5 to < 12 years 3306 (20.2%) 773 (15.9%) 201 (16.5%) 1264 (13.9%) 5544 (17.6%)
 ≥ 12 years 3491 (21.3%) 862 (17.8%) 426 (34.9%) 3665 (40.4%) 8444 (26.8%)
 Missing 23 (0.1%) 8 (0.2%) 6 (0.5%) 13 (0.1%) 50 (0.2%)
Continenta
 Africa 14,087 (86.0%) 4550 (93.8%) 810 (66.4%) 4862 (53.6%) 24,309 (77.2%)
 Asia 2127 (13.0%) 300 (6.2%) 410 (33.7%) 3950 (43.6%) 6787 (21.5%)
 South America 159 (1.0%) 0 (0.0%) 0 (0.0%) 252 (2.8%) 411 (1.3%)
Enrolment clinical parameters
 Mean body weight ± SD (kg) 20.9 ± 16.29 20.0 ± 16.02 23.7 ± 17.2 22.4 ± 17.55 21.2 ± 16.63
 Mean haemoglobin ± SD (g/dL) 10.2 ± 2.21 9.6 ± 1.98 10.4 ± 2.26 10.2 ± 2.31 10.1 ± 2.22
 Median parasitaemia [IQR] (/µL) 19,674 [5590–50,550] 21,730 [7353–53,439] 23,386 [5953–64,103] 14,320 [4178–43,337] 18,576 [5284–49,520]
 Elevated temperature (> 37.5°) 64.3% [9705/15,101] 67.9% [3221/4747] 74.0% [743/1004] 60.2% [4200/6972] 64.2% [17,869/27,824]
Fig. 2 The observed proportion of recurrence events in the studies 
included. The distribution of observed proportion of recrudescences, 
new infections and indeterminate outcomes from 233 study arms 
included in the analysis
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required to meet for introducing a regimen as a first line 
therapy) using the K–M method, all of which were less 
than 5% using the CIF.
Risk of Plasmodium falciparum new infection
The median overestimation of the cumulative risk 
of new P. falciparum infections during the follow-
up period using the K–M method (which considered 
recrudescences as censored) compared to the Cumula-
tive Incidence Function was 0.39% [IQR: 0.08–1.10%; 
Range: 0.00–10.60%]. The overestimation progres-
sively increased with the follow-up duration, which was 
0.10% on day 28, 0.67% on day 42, and 1.40% on day 63 
(Fig. 3; lower panels). The overestimation increased with 
increasing proportion of patients with new infections 
and recrudescences observed in a study. The maximum 
overestimation was 10.6%, observed in a study with 
artemether–lumefantrine (n = 50) carried out in Tanza-
nia. In this study arm, there were 9 (18%) recrudescences, 
and 29 (58%) new infections. Using the 1 minus K–M 
method, the risk of new infection on day 42 was 68.6% 
[95% CI 54.3–83.1] and this was 58.0% [95% CI 44.2–
71.7] using the CIF method.
Comparative efficacy studies
The results of the comparative efficacy studies are pre-
sented in Additional file  3: Section  2. There was no 
difference in the overall conclusion derived (at 5% level 
of significance) using the two approaches for testing for 
equality between the drug regimens using the log-rank 
test and Gray’s k-sample test.
Regression models for time to recrudescence
Data from 810 children enrolled in Burkina Faso (a sub-
set of the The 4ABC Trial [18]) treated with artemether–
lumefantrine (AL) (n = 294), artesunate–amodiaquine 
(ASAQ) (n = 295) and dihydroartemisinin–piperaquine 
(DP) (n = 221) were used to illustrate the regression 
modelling approaches in the presence of competing risk 
events. The observed proportion of patients with recru-
descences were 3.2% in the DP arm, 8.2% in the AL arm, 
and 3.1% in the ASAQ arm, while the respective propor-
tion for new infections were 10.0%, 48.3%, and 25.1% 
(Table  5). In a multivariable model for recrudescence 
(which included age, baseline parasitaemia and treat-
ment regimen), age and baseline parasitaemia did not 
reach conventional statistical significance for recrudes-
cence, neither in the cause-specific hazard model nor 
in the sub-distribution hazard model (P-value > 0.05). 
Treatment with AL (relative to DP) was associated with 
increased cause-specific hazard and increased sub-dis-
tribution hazard of recrudescence (csHR = 4.02 [95% CI 
1.72–9.43]; sdHR = 2.85 [95% CI 1.24–6.57]).
Table 3 Absolute overestimation (%) in cumulative recrudescence estimates using K–M analysis compared to Cumulative 
Incidence Function
N number of study sites with study sample size ≥ 25, AL artemether–lumefantrine, ASAQ artesunate–amodaiquine, DP dihydroartemisinin–piperaquine, ASMQ 
artesunate–mefloquine, IQR interquartile range
a Values are median [Interquartile Range (IQR); Range] for FˆKM(t)− FˆCIF (t)
b Values are median [Range]
N Absolute  overestimationa Observed proportion 
of  recrudescenceb
Observed proportion 
of competing risk 
 eventsb
Day 28
 AL 88 0.02% [IQR: 0.00–0.12%; Range: 0.00–2.54%] 2.1% [0.1–16.0%] 9.8% [0.0–51.4%]
 ASAQ 21 0.03% [IQR: 0.00–0.10%; Range: 0.00–0.98%] 2.5% [0.3–12.8%] 10.2% [0.0–45.4%]
 ASMQ 8 0.00% [IQR: 0.00–0.03%; Range: 0.00–0.08%] 1.9% [0.8–7.0%] 11.0% [6.3–14.0%]
DP 30 0.00% [IQR: 0.00–0.00%; Range: 0.00–0.16%] 1.3% [0.4–16.4%] 2.7% [0.0–36.8%]
Day 42
 AL 48 0.25% [IQR: 0.03–0.65%; Range: 0.00–3.24%] 3.7% [0.6–18.0%] 21.6% [0.0–65.4%]
 ASAQ 9 0.23% [IQR: 0.02–0.69%; Range: 0.00–2.24%] 3.3% [1.0–17.0%] 18.4% [2.3–65.2%]
 ASMQ 8 0.25% [IQR: 0.12–0.50%; Range: 0.00–1.03%] 3.7% [1.4–11.3%] 25.3% [1.0–43.3%]
 DP 21 0.00% [IQR: 0.00–0.19%; Range: 0.00–0.73%] 1.9% [0.8–16.4%] 7.1% [0.0–34.6%]
Day 63
 AL 9 0.96% [IQR: 0.65–1.38%; Range: 0.012–3.42%] 3.7% [1.4–10.6%] 7.1% [0.0–34.6%]
 ASAQ 2 0.18% [IQR: 0.09–0.27%; Range: 0.00–0.36%] 12.3% 18.5%
 ASMQ 7 0.98% [IQR: 0.38–2.20%; Range: 0.21–3.59%] 4.1% [1.6–12.7%] 4.1% [1.6–12.7%]
 DP 8 0.14% [IQR: 0.01–0.38%; Range: 0.00–0.89%] 2.2% [1.6–12.7%] 7.1% [3.4–30.0%]
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The regression models presented in Table 5 were used 
for predicting the risk of recrudescence on day 28 for 
a patient aged 3  years old with an initial parasite load 
of 100,000/µL. For the DP regimen, the predicted risk 
for a patient with this covariate profile was 4.3% using 
the cause-specific Cox proportional hazard model, and 
3.9% using the sub-distribution hazard model (Fig.  4). 
For the AL regimen, the predicted risks were 16.2% and 
10.7% using the cause-specific and sub-distribution haz-
ard models respectively. For ASAQ, the estimates of 
predicted risks were 4.8% using the cause-specific Cox 
model and 3.9% using the Fine and Gray’s sub-distribu-
tion hazard model.
Discussion
Recent reviews have shown that the majority of studies 
published in medical journals are susceptible to compet-
ing risk biases [6, 16, 22]; a concept hitherto overlooked 
in malaria literature. This re-analysis of individual patient 
data of 233 treatment arms from 92 clinical efficacy 
studies conducted in Asia, Africa, and South America 
revealed that just over a third (83/233) of the treatment 
arms had an observed proportion of new infection 
greater than 10%, a threshold considered to make studies 
vulnerable to competing risk bias [23]. This suggests that 
competing risk events are the rule rather than the excep-
tion in antimalarial trials.
This analysis allowed the exploration of the degree 
to which the derived estimate of failure was affected by 
ignoring the competing risk events in analysis of antima-
larial efficacy trials. The K–M analysis which censored 
new infections was associated with a marginal absolute 
overestimation of the cumulative risk of recrudescence. 
In 9% (21/233) of the study arms the overestimation 
was greater than 1%, in 4.3% (10/233) the difference was 
greater than 2%, and in 2.6% (6/233) of the arms the dif-
ference was greater than 3%. All but one of the 21 study 
sites where the difference exceeded 1% were from Africa 
Fig. 3 The overestimation of derived failure by 1 minus Kaplan–Meier method compared to the Cumulative Incidence Function. The overestimation (
FˆKM(t)− FˆCIF (t)
)
 of cumulative recrudescence (top panel) and new infection (bottom panel) by using the Kaplan–Meier method plotted against 
observed proportion of recrudescence and proportion of new infections respectively. Estimates presented are at the end of the study follow-up. 
The grey trend line is a smoothed estimator obtained from local polynomial regression fitting, shown together with 95% confidence interval (outer 
dotted lines) for the overall data. AL artemether–lumefantrine, ASAQ artesunate–amodiaquine, DP dihydroartemisinin–piperaquine, ASMQ 
artesunate–mefloquine. Data are shown from the study arms where at least one recrudescence and at least one competing risk event were 
observed and from those arms where the number of patients at risk > 25 on the last day of the study follow-up
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(areas of intense malaria transmission), the exception 
being a study from Papua New Guinea where a very high 
proportion of patients experienced recurrent parasi-
taemia due to P. vivax. The degree to which K–M over-
estimated failure in a study arm was correlated with the 
proportion of patients experiencing new infection or 
recrudescence, and the follow-up duration; these findings 
are consistent with the literature [1].
The current WHO guidelines recommend that when 
the estimates of recrudescence at the end of the follow-
up exceed 10%, a series of detailed clinical, pharmaco-
logical and in  vitro investigations should  be undertaken 
Table 4 Study sites where cumulative failure estimates exceeded 10% and 5% using K–M approach
N study sample size, RC recrudescence, NI new infection, IND indeterminate outcomes, FˆKM(t) cumulative failure estimates derived using 1 minus Kaplan–Meier 
method, FˆCIF (t) cumulative failure estimates derived using Cumulative Incidence Function, AL artemether–lumefantrine, ASMQ artesunate–mefloquine
a  The 10% threshold is used by the WHO for determining whether the current regimen should be continued to be used as a first line therapy and 5% threshold is 
used for introducing a new regimen as a first line treatment [50]
b  Unpublished study
Study (site) N Number 
of events (RC/
NI/IND)
Day Drug FˆKM(t) estimate 
of recrudescence [95% 
confidence interval]
FˆCIF(t) estimate 
of recrudescence [95% 
confidence interval]
10%  thresholda
 Nikiema-2010 (Burkina Faso, Gourcy)b 144 12/28/3 28 AL 10.3 [4.8–15.8] 9.4 [4.3–14.5]
 The 4ABC Trial (Burkina Faso, Nanoro) [18] 294 24/142/9 28 AL 11.1 [6.8–15.4] 8.6 [5.3–11.8]
 Sirima-2015 (Burkina Faso, Balonghin) [21] 66 31/5/0 63 ASMQ 11.5 [7.2–15.9] 8.1 [1.2–14.9]
5%  thresholda
 Yeka-2008 (Uganda, Kanungu) [45] 199 9/49/6 42 AL 5.2 [1.9–8.5] 4.6 [1.7–7.6]
 Sirima-2015 (Tanzania, Korogwe) [21] 27 1/3/2 63 AL 5.0 [0.0–14.6] 4.3 [0.0–12.9]
 Schramm-2013 (Liberia, Nimba) [46] 145 7/45/6 42 AL 5.6 [1.5–9.7] 5.0 [1.4–8.6]
 Agrawal-2013 (Kenya, Siaya) [47] 136 5/48/12 42 AL 5.2 [0.5–10.0] 4.2 [0.6–7.8]
 Karunajeewa-2008 (PNG, Madang) [48] 54 2/20/0 42 AL 5.9 [0.0–14.3] 4.7 [0.0–11.3]
 Sirima-2015 (Kenya, Kisumu) [21] 99 4/23/9 63 ASMQ 6.1 [0.1–12.0] 4.8 [0.2–9.4]
 Sirima-2015 (Burkina Faso, Balonghin) [21] 128 5/58/1 63 AL 5.4 [0.7–10.2] 4.0 [0.6–7.5]
 Bukirwa-2006 (Uganda, Tororo) [49] 204 10/89/2 28 AL 6.6 [2.6–10.7] 4.9 [2.0–8.0]
 Sirima-2015 (Kenya, Ahero) [21] 73 3/28/10 63 ASMQ 7.8 [0.0–16.7] 4.7[0.0–10.0]
Table 5 Regression models for recrudescence and new infection using data from Burkina Faso (n = 810) [18]
AL artemether–lumefantrine, DP dihydroartemisinin–piperaquine, ASAQ artesunate–amodiaquine
Observed 
proportion 
of events
Cause-specific Cox proportional 
hazard model
Fine and Gray’s sub-distribution 
hazard model
Cause-specific HR [95% 
confidence interval]
P-value Sub-distribution HR 
[95% confidence 
interval]
P-value
Model for recrudescence
 Age (/yearly increase) 4.9% (40/810) 0.99 [0.77–1.29] 0.965 1.00 [0.80–1.25] 0.990
 Baseline parasitaemia (/µL) (tenfold increase) 4.9% (40/810) 1.67 [0.88–3.16] 0.114 1.44 [0.84–2.46] 0.190
 Treatment (ref = DP) 3.2% (7/221)
  AL 8.2% (24/294) 4.02 [1.72–9.43] 0.001 2.85 [1.24–6.57] 0.014
  ASAQ 3.1% (9/295) 1.12 [0.42–2.99] 0.829 1.01 [0.38–2.69] 0.980
Model for new infection
 Age (/yearly increase) 29.4% (238/810) 1.08[0.98–1.21] 0.121 1.08[0.99–1.19] 0.093
 Baseline parasitaemia (/µL) (tenfold increase) 29.4% (238/810) 1.52[1.18–1.97] 0.001 1.40[1.10–1.78] 0.006
 Treatment (ref = DP) 10.0% (22/221)
  AL 48.3% (142/294) 8.05[5.12–12.67] < 0.001 6.51[4.27–9.94] < 0.001
  ASAQ 25.1% (74/295) 3.03[1.88–4.88] < 0.001 2.83[1.80–4.44] < 0.001
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to examine the possibility of parasite drug resistance. If 
resistance is confirmed, then treatment policy should be 
revised to a more effective regimen [2]. In three study 
arms, the estimated failure was greater than 10% (the 
WHO threshold for withdrawing antimalarials) when the 
K–M method was used, but remained below 10% when 
using a competing risk survival analysis method with the 
95% confidence interval for the two estimates overlap-
ping and the estimated 95% confidence interval included 
this threshold (Table 4). However, if the clinical decision-
making was based solely on the point-estimates, then this 
highlights that ignoring competing risk events can result 
in potentially misleading conclusions being drawn from 
an efficacy trial, especially when the derived estimates are 
at the cusp of these thresholds.
The effect of competing risk events in comparative 
settings was then evaluated, as the partner components 
of the ACT are eliminated at different rates resulting in 
a differential fraction of new infections observed. For 
example, lumefantrine has a much shorter terminal 
elimination half-life compared to piperaquine [24]. The 
underlying drug pharmacokinetics will result in a  lower 
observed proportion of new infections following DP 
administration compared to the AL regimen, especially in 
areas of intense malaria transmission [25]. This highlights 
the importance of taking the proportion of competing 
risk events into consideration when comparing drug regi-
mens with different pharmacological properties. In order 
to explore whether these pharmacological differences 
affected the comparative analyses of these two drugs, the 
equality of the survival curves was  compared using the 
log-rank test and Gray’s k-sample test using data from 27 
comparative studies. There were no apparent differences 
in the derived conclusions using these two approaches as 
there were very few observed recrudescences in each of 
the study arms (Additional file 3: Section 2).
Finally, two different approaches to regression model-
ling in the presence of competing risk events were  pre-
sented using data from Burkina Faso: the regression 
model on cause-specific hazard and on the sub-distribu-
tion hazard. The estimates of the sub-distribution hazard 
ratio (sdHR) were somewhat attenuated and closer to the 
null value compared to the cause-specific hazard ratio 
(csHR) (Table  5). Although the relative risk measures 
Fig. 4 Predicted risk of recrudescence from cause-specific Cox model and sub-distribution hazard model. The graph was generated using the 
regression coefficients presented in Table 5 and the estimate of baseline hazard obtained from the respective sub-distribution and cause-specific 
hazard model (for a 3 year old child). The cumulative baseline sub-distribution hazard on day 28 from Fine and Gray’s model was 0.006; the 
cumulative baseline hazard on day 28 from the cause-specific Cox model was 0.003. The vertical dotted line represents the parasitaemia of 100,000/
µL for the child described in the main text. On day 28, the predicted risk of recrudescence for this patient was 16.15%, 4.76% and 4.28% using the 
cause-specific Cox model. The corresponding figures were 10.72%, 4.76% and 4.28% with the Fine and Gray’s sub-distribution hazard model. AL 
artemether–lumefantrine, ASAQ artesunate–amodiaquine, DP dihydroartemisinin–piperaquine
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(cause-specific hazard ratio and sub-distribution hazard 
ratio) obtained from these two regression models were 
similar (Table 5), they are not directly comparable as they 
have a different interpretation [26, 27]. In the illustrated 
example, the csHR of 1.67 for baseline parasitaemia 
implies that every tenfold rise in parasite load was associ-
ated with a 1.67-fold higher risk of recrudescence, among 
patients who had not experienced any recurrence yet by 
the end of the follow-up. The sdHR of 1.44 (higher than 
1) means that the cumulative incidence of recrudescence 
increases with every tenfold increase in parasite density 
and the interpretation of the numeric value of 1.44 is not 
straight forward [26]. This is because subjects who have 
experienced new infections are still maintained in the 
risk-set when computing a sub-distribution hazard, even 
though they are no longer at risk of experiencing recru-
descence (Additional file 1: Section 3).
In the presence of competing risk events, researchers 
are faced with a choice of methods, and this has gathered 
considerable attention in medical and statistical literature 
[10, 17, 28–30]. In comparative studies, the log-rank test 
is considered appropriate when the research interest is in 
understanding the biological mechanism of how a treat-
ment affects recrudescence (hazard rate). If the research 
interest is to answer if subjects receiving a particular drug 
are more likely to experience recrudescence at the end 
of the study follow-up, the comparison of CIF through 
Gray’s k-sample test is considered appropriate [1, 31, 32]. 
Many authors advocate presenting results of both these 
approaches to provide a complete biological understand-
ing of the treatment on the different endpoints [1, 33]. 
For regression models, if the aim is to estimate prob-
ability and provide evidence to inform medical decision-
making, the use of sub-distributional hazard model has 
been advocated as the method of choice [27, 34, 35], and 
if the aim is to explore the underlying biological effects of 
a covariate on the outcome, then a regression model on 
the cause-specific hazard has been preferred [1, 26, 27, 
34].
This analysis has a number of limitations. It was 
assumed that the outcome of molecular genotyp-
ing reflects the true treatment outcomes. The current 
approach to parasite genotyping applies a conservative 
approach which overestimates the recrudescence par-
ticularly in areas of intense malaria transmission [36, 37]. 
In areas of very high transmission, such as Uganda, para-
site infections are frequently polyclonal and as many as 
45% of the recrudescences could be misclassified as new 
infections [38]. Further difficulties arise when the sub-
sequent recrudescence is due to a minority clone which 
was undetected at baseline, thus leading to misclassified 
outcomes. This necessitates incorporating the uncertain-
ity around the outcome classification, such as by using 
a Bayesian approach for classification of late treatment 
failures [39]. Indeterminate outcomes were censored 
in K–M analysis and considered as an extra category of 
competing risk event when generating CIF. An indeter-
minate outcome can only be considered as a competing 
risk event if the new infection and recrudescence coin-
cide. However, an indeterminate outcome arising for 
other reasons, such as missing pairwise samples, or fail-
ure to amplify the parasite DNA cannot be considered 
as competing events in sensu stricto. In such a situation, 
considering them as an extra category for CIF analy-
sis might have introduced bias. The efficacy of ACT in 
uncomplicated falciparum malaria remains high, with 
treatment failure reported in less than 5% of patients in 
the vast majority of ACT studies included in this analysis. 
Hence, the data used in this re-analysis did not allow the 
investigation of what would happen when the antimalar-
ial efficacy declines. In order to quantify the magnitude 
of the potential biases in situations of falling antimalarial 
efficacy (now observed for dihydroartemisinin–pipe-
raquine in Cambodia and Vietnam [40–42]), simulation 
studies were conducted and reported elsewhere [43]. This 
study did not explore the scenario of multiple-failure time 
(multivariate survival data), in which each patient can 
experience multiple events during follow-up. This sce-
nario is of low relevance for falciparum malaria, but mul-
tiple events frequently occur in trials of vivax malaria, in 
which a patient may experience multiple relapses due to 
reactivation of hypnozoites from the liver.
Finally, it is difficult to disentangle whether a new 
infection is a truly competing endpoint in a biological 
sense. In a situation where the parasite causing the initial 
infection is subdued at low density and the newly emerg-
ing infection has higher density than the subdued origi-
nal infection, then on a strong assumption of identical 
parasite multiplication rate for both infections, this con-
stitutes a situation where the occurrence of new infec-
tion precludes recrudescence (Fig.  1a). This assumption 
of identical parasite multiplication rates might be plau-
sible for rapidly eliminated drugs. For slowly eliminated 
drugs, the parasite growth rate for recrudescence and a 
new infection are likely to be different. Similarly, a recru-
descent infection where the parasite numbers never go 
below those encountered at the beginning of a new infec-
tion cannot be pre-empted and the occurrence of recru-
descence will not be affected (Fig. 1b). The only exception 
is if the new infection is more resistant than the pri-
mary infection. When the initial infection is completely 
eliminated after exposure to antimalarials, the host is no 
longer at a risk of subsequent recrudescence and com-
peting risk situation does not exist (Fig. 1c). In reality it 
is impossible to disentangle the underlying in vivo para-
sitological circumstances from this dataset. Thus, new 
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infections can be considered as a “situational competing 
risk event” which is primarily dependent on the inoculum 
density, fitness, efficiency of a newly emergent infection 
and of the existing recrudescent parasites, and the host 
immunity.
Conclusions
Censoring competing events in the Kaplan–Meier analy-
sis led to an overestimation of the risk of recrudescence, 
which was of marginal clinical importance in the data 
included in this analysis. In the areas of high transmission 
where a large proportion of recurrences are attributable 
to new infections, the use of CIF provides an alternative 
approach for the derivation of failure estimates for anti-
malarial treatments.
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